{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T14:35:17Z","timestamp":1782311717108,"version":"3.54.5"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Despite the growing adoption of HIFU treatment for localized prostate cancer (PC), standardized criteria for evaluating success and predicting recurrence remain undefined. Herein, we analyze the predictive value of noninvasive tools such as PSA dynamics and MRI to determine recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We identified from our HIFU therapy prospective registry patients who developed biopsy-proven recurrence, between 2016 and 2023. Clinically significant recurrence (CS-R) was defined as the presence of GG 2 or greater on control biopsy. Different modalities of PSA kinetics were analyzed and determinants for recurrence were based on either PSA or MRI criteria (PIRADS\u2009&gt;\u20093). Sensitivity, specificity, PPV, and NPV were estimated based on single or combined criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      92 patients were included in the study. A total of 17(18%) patients had CS-R. Those patients presented higher PSA velocity (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and a higher proportion of PSA above nadir\u2009+\u20091 at 12 months (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001). Static PSA measurement and % of PSA drop were not associated with recurrence. Follow-up based on a combination of PSA parameters (PSA below nadir\u2009+\u20091) and MRI criteria had higher sensitivity (88%) and negative predictive value (96%) in detecting post-treatment recurrence. Limitation of the study included limited number of patients and a relatively short follow up period.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Post-HIFU recurrence surveillance through dynamic PSA monitoring shows better predictive value. Implementing \u2018for cause\u2019 surveillance biopsies guided by dynamic PSA changes along with mpMRI appears to enhance the detection of recurrences without missing a significant number of cases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00345-025-05529-0","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T01:06:46Z","timestamp":1741741606000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Use of biochemical and imaging criteria for selecting patients for prostate biopsy in recurrence risk assessment post-HIFU therapy"],"prefix":"10.1007","volume":"43","author":[{"given":"Tarek","family":"Ajami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan T.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nachiketh Soodana","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archan","family":"Khandekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keerthana","family":"Sureshkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad R.","family":"Ritch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark L.","family":"Gonzalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanoj","family":"Punnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipen J.","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Nahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"5529_CR1","doi-asserted-by":"publisher","unstructured":"Reddy D, Peters M, Shah TT et al (2022) Cancer control outcomes following focal therapy using High-intensity focused ultrasound in 1379 men with nonmetastatic prostate cancer: a multi-institute 15-year experience. Eur Urol 81(4):407\u2013413. https:\/\/doi.org\/10.1016\/j.eururo.2022.01.005","DOI":"10.1016\/j.eururo.2022.01.005"},{"key":"5529_CR2","doi-asserted-by":"publisher","unstructured":"Guillaumier S, Peters M, Arya M et al (2018) A multicentre study of 5-year outcomes following focal therapy in treating clinically significant nonmetastatic prostate. Cancer Eur Urol 74(4):422\u2013429. https:\/\/doi.org\/10.1016\/j.eururo.2018.06.006","DOI":"10.1016\/j.eururo.2018.06.006"},{"key":"5529_CR3","doi-asserted-by":"publisher","unstructured":"Nahar B, Ajami T, Williams A et al (2024) Survival outcomes and recurrence patterns following focal high-intensity focused ultrasound treatment for localized prostate cancer: insights on patient selection and lessons learned. Eur Urol Focus S2405-4569(24)00246\u20133 https:\/\/doi.org\/10.1016\/j.euf.2024.11.005","DOI":"10.1016\/j.euf.2024.11.005"},{"key":"5529_CR4","doi-asserted-by":"publisher","unstructured":"Light A, Mayor N, Cullen E et al (2024) The transatlantic recommendations for prostate gland evaluation with magnetic resonance imaging after focal therapy (TARGET): a systematic review and international consensus recommendations. Eur Urol 85(5):466\u2013482. https:\/\/doi.org\/10.1016\/j.eururo.2024.02.001","DOI":"10.1016\/j.eururo.2024.02.001"},{"key":"5529_CR5","doi-asserted-by":"publisher","unstructured":"Nicoletti R, Alberti A, Castellani D et al (2023) Oncological results and cancer control definition in focal therapy for prostate cancer: a systematic review prostate. Cancer Prostatic Dis https:\/\/doi.org\/10.1038\/s41391-023-00699-7","DOI":"10.1038\/s41391-023-00699-7"},{"key":"5529_CR6","doi-asserted-by":"publisher","unstructured":"Ghoreifi A, Kaneko M, Peretsman S et al (2023) Patient-reported satisfaction and regret following focal therapy for prostate cancer: a prospective multicenter evaluation. Eur Urol Open Sci 50:10\u201316, https:\/\/doi.org\/10.1016\/j.euros.2023.02.003","DOI":"10.1016\/j.euros.2023.02.003"},{"key":"5529_CR7","doi-asserted-by":"publisher","unstructured":"Ehdaie B, Tempany CM, Holland F et al (2022) MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study. Lancet Oncol 23(7):910\u2013918 https:\/\/doi.org\/10.1016\/S1470-2045(22)00251-0","DOI":"10.1016\/S1470-2045(22)00251-0"},{"key":"5529_CR8","doi-asserted-by":"publisher","unstructured":"Rischmann P, Gelet A, Riche B et al (2017) Focal high intensity focused ultrasound of unilateral localized prostate cancer: a prospective multicentric hemiablation study of 111 patients. Eur Urol 71(2):267\u2013273. https:\/\/doi.org\/10.1016\/j.eururo.2016.09.039","DOI":"10.1016\/j.eururo.2016.09.039"},{"key":"5529_CR9","doi-asserted-by":"publisher","unstructured":"Nahar B, Bhat A, Reis IM et al (2020) Prospective evaluation of focal high intensity focused ultrasound for localized prostate cancer. J Urol 204(3):483\u2013489. https:\/\/doi.org\/10.1097\/JU.0000000000001015","DOI":"10.1097\/JU.0000000000001015"},{"key":"5529_CR10","doi-asserted-by":"publisher","unstructured":"Connolly D, Black A, Murray LJ, Napolitano G, Gavin A, Keane PF (2007) Methods of calculating prostate-specific antigen velocity. Eur Urol 52(4):1044\u20131050 https:\/\/doi.org\/10.1016\/j.eururo.2006.12.017","DOI":"10.1016\/j.eururo.2006.12.017"},{"key":"5529_CR11","doi-asserted-by":"publisher","unstructured":"Morgan TM, Boorjian SA, Buyyounouski MK et al (2024) Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO guideline part i: introduction and treatment decision-making at the time of suspected biochemical recurrence after radical prostatectomy. J Urol 211(4):509\u2013517 https:\/\/doi.org\/10.1097\/JU.0000000000003892","DOI":"10.1097\/JU.0000000000003892"},{"key":"5529_CR12","doi-asserted-by":"publisher","unstructured":"Huber PM, Afzal N, Arya M et al (2020) Prostate specific antigen criteria to diagnose failure of cancer control following focal therapy of nonmetastatic prostate cancer using high intensity focused ultrasound. J Urol 203(4):734\u2013742 https:\/\/doi.org\/10.1097\/JU.0000000000000747","DOI":"10.1097\/JU.0000000000000747"},{"key":"5529_CR13","doi-asserted-by":"publisher","unstructured":"Schaudinn A, Michaelis J, Franz T et al (2021) High-intensity focused ultrasound (HIFU) hemiablation of the prostate: late follow-up MRI findings in non-recurrent patients. Eur J Radiol 144:109957. https:\/\/doi.org\/10.1016\/j.ejrad.2021.109957","DOI":"10.1016\/j.ejrad.2021.109957"},{"key":"5529_CR14","doi-asserted-by":"publisher","unstructured":"Giganti F, Dickinson L, Orczyk C et al (2023) Prostate imaging after focal ablation (PI-FAB): a proposal for a scoring system for multiparametric mri of the prostate after focal therapy. Eur Urol Oncol 6(6):629\u2013634 https:\/\/doi.org\/10.1016\/j.euo.2023.04.007","DOI":"10.1016\/j.euo.2023.04.007"},{"key":"5529_CR15","unstructured":"Jafarvand M, Farolfi A, Benz M et al (2023) \u2009PSMA PET\/CT for prostate cancer patients after focal therapy: a single center retrospective analysis. J Nucl Med 64(1):P1241"},{"key":"5529_CR16","doi-asserted-by":"publisher","unstructured":"Ajami T, Blachman-Braun R, Porto JG et al (2024) Combined holmium laser enucleation of the prostate with high-intensity focused ultrasound in treating patients with localized prostate cancer in a prostate with volume\u2009>\u200960\u00a0g: Oncological and functional outcomes from single-institution study. Urol Oncol 42(9):289. https:\/\/doi.org\/10.1016\/j.urolonc.2024.04.022","DOI":"10.1016\/j.urolonc.2024.04.022"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05529-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05529-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05529-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:53:31Z","timestamp":1767966811000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05529-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5529"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05529-0","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"assertion":[{"value":"10 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"162"}}